Donaueschingen (pta/07.11.2023/08:45 UTC+1)
Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its sales by 14% and EBT by approx. 33% in the first nine months of 2023. As a result, the continually positive development of sales and earnings of the last years could be continued.
Sales improved from KEUR 150,790 to KEUR 171,266 (+13.6%) in the first nine months 2023. The international share of total business volume was 47.2% (9M-2022: 47.5%) and amounted to KEUR 80,793 compared to KEUR 71,551 (9M-2022). Acquired sales amounting to KEUR 4,790 were consolidated in the reporting period. Organic growth amounted to 10.4%.
New long-term Software-as-a-Service (SaaS) contracts were concluded in 2023 amounting to KEUR 3,750 per year.
The consolidated surplus rose very sharply by 26.1% to KEUR 17,465 (9M-2022: KEUR 13,845), and consolidated earnings before interest and taxes (EBIT) rose by 18.9% to KEUR 22,352 (9M-2022: KEUR 18,794): EBITA increased by 18.9% from KEUR 22,351 (9M-2022) to KEUR 26,583, and EBITDA increased by 13.5% to KEUR 35,454 (9M-2022 KEUR 31,236).
As of 30/09/2023, the company had cash resources at its disposal in the amount of KEUR 98,830 (31/12/2022: KEUR 110,019). Nexus AG had equity capital amounting to KEUR 251,601 as of 30/09/2023 (31/12/2022: KEUR 238,946). Consequently, the equity capital rate is 63.0% (31/12/2022: 69.4%).
The detailed quarterly report can be found on our homepage at: https://www.nexus-ehealth.com/company/investor-relations
Donaueschingen, 7th November
The Managing Board
|Contact Person:||Hannes Wehinger|
|Phone:||+49 771 22960-260|
|Stock Exchange(s):||Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate|